TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06375044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0500
Description: Participants will receive SIM0500 in a 28-day cycle until disease progression, intolerable toxicity, or until the participant voluntarily withdraws from trial intervention, or end of study, whichever comes first.
Study: NCT05722327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: Given by PO (mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: Given by PO (mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV (vein)
Study: NCT06005792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb27564
Description: Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb27564
Description: Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).
Study: NCT05697406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
Study: NCT04982224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5093-M114
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5093-M114
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered by IV infusion
Study: NCT05846412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation and M-TEER
Description: Already included in arm descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter Ablation and M-TEER
Description: Already included in arm descriptions.
Study: NCT05605366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
Study: NCT06085222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Engagement Distress Tolerance Intervention
Description: 2.5 hour computerized intervention with smart phone support focused on building tolerance of emotional distress

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education Intervention
Description: 2.5 hour computerized intervention with smart phone support focused on building healthy habits that support stress management
Study: NCT06135935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-added-sugar ice cream
Description: The initial focus of this clinical trial will be the impact on postprandial glycaemia of 300g of ice cream, since, from a nutrition perspective, the flavored milks and ice creams are very similar in composition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional products
Description: The overconsumption of sugar-added conventional products leads to an increased risk of poor control of glycaemic levels.
Study: NCT06371846

Intervention type: OTHER
Intervention: Selected signals from Pacing System Analyzers
Description: Comparative observational, prospective, multicenter study between the signals obtained by PSA vs MPS of consecutive patients who underwent a LBBAP strategy as first intention.
Study: NCT05722548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Description: 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT04370106

Intervention type: OTHER
Group type: OTHER
Intervention: Social leg program
Description: Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
Study: NCT04756648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT0180 Cells
Description: Five dose levels were tentatively determined.
Study: NCT05179148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
Study: NCT05745259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase 0.9mg/kg are being used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg are being used.
Study: NCT04967092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Xiao-Feng Powder + Antiallergics
Description: Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Antiallergics
Description: Placebo granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
Study: NCT06298175

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self management training
Description: The self-management training programme for the study group consisted of eight sessions. Each session lasted between 40 and 50 minutes and followed a structured format: a 5-minute introduction, a 5-minute summary of the previous session, and a 30-40 minute presentation on the session's topic. Training plan on cognition, emotion regulation and self-management was implemented

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management training
Description: The self-management training programme for the study group consisted of eight sessions. Each session lasted between 40 and 50 minutes and followed a structured format: a 5-minute introduction, a 5-minute summary of the previous session, and a 30-40 minute presentation on the session's topic. Training plan on cognition, emotion regulation and self-management was implemented
Study: NCT05286242

Intervention type: BIOLOGICAL
Intervention: COVID19 vaccine
Description: All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.

Intervention type: BIOLOGICAL
Intervention: COVID19 vaccine
Description: All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.

Intervention type: BIOLOGICAL
Intervention: COVID19 vaccine
Description: All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.

Intervention type: BIOLOGICAL
Intervention: COVID19 vaccine
Description: All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.
Study: NCT06484660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Approach In The Mucosal Advancement Flap Technique
Description: Surgical treatment of complex perianal fistula. Less tissue damage. Electrocoagulation source with 75% lower power. Better de-epithelialization of the intra-sphinteric tract. More precise closure of orifice. More consistent mucosal flap
Study: NCT05809635

Intervention type: OTHER
Intervention: Natural History Study
Description: Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
Study: NCT06636708

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nanodropper and Proparacaine HCl 0.5%
Description: The Nanodropper is an eyedrop bottle adaptor that creates smaller eyedrops by coupling to an existing eyedrop bottle. This intervention involves the administration of proparacaine HCl 0.5% using the Nanodropper.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Eye Drop Bottle with Proparacaine HCl 0.5%
Description: This intervention involves administration of proparacaine HCl 0.5% using a standard eye drop bottle.
Study: NCT05585827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral therapy
Description: The e-CBT treatment manual is an adjusted version of a previously published treatment manuals for neuropsychiatric symptoms in PD, which is tailored to the preferences and needs for each participant. This manual encompass both modules from manuals for depression in PD and anxiety in PD. Individualization is ensures by including several interventions modules in the manual, wherein 5 sessions are considered core modules, and four modules that can be offered depending on the patients individual needs. The participant may include partners or caregivers. The treatment is schedules to be completed within 13 weeks, with maximum ten sessions during this period. Following each e-CBT session, the participant will be asked to complete a short survey evaluating the acceptability and relevance of the session, and evaluate the therapeutic alliance.
Study: NCT04954898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT
Description: Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
Study: NCT04947709

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity
Description: The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
Study: NCT06103006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to \>1 set).
Study: NCT05072353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEFFICARE
Description: The SEFFI is a 5-step technique:~1. Preparation: the lower/lateral abdomen is chosen as the donor site.~2. Anesthesia: the donor site is injected with a local anesthetic.~3. Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~4. Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~5. Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound.
Study: NCT06330194

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2nd Generation Automated Insulin Delivery (AID) system
Description: The AID system will initially commence delivery by insulin pump post-randomisation without the AID in operation and with predictive low glucose suspend activated for a period of two weeks. Once safety has been established, the autocorrect function can be activated and the setpoint reduced to 5.5 mmol/L. Throughout the study insulin pump uploads will be reviewed twice weekly initially and at least weekly thereafter.
Study: NCT05414643

Intervention type: OTHER
Intervention: Standard care
Description: No interventions were used, as this is an observational study.

Intervention type: OTHER
Intervention: Standard care
Description: No interventions were used, as this is an observational study.
Study: NCT05179421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose oxytocin
Description: 10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose oxytocin
Description: 10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose oxytocin
Description: 10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose oxytocin
Description: 10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
Study: NCT06496126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerasmart 270 (GC Coop, Tokyo, Japonya)
Description: Hybrid Ceramic Block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EverX Flow (GC Coop, Tokyo, Japonya)
Description: Fiber Reinforced Composite Resin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: : G-CEM ONE (GC Coop, Tokyo, Japonya)
Description: Universal Self Adhesive Resin Cement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-Premio Bond (GC Coop, Tokyo, Japonya)
Description: Universal Adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-ænial A'CHORD
Description: Conventional Composite Resin
Study: NCT05835856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual coach with NAO robot
Description: The coaching device used is the softbank NAO 5 and NAO 6 humanoid interactive mobile robot. These robot platform allows multimodal natural language interaction and robot autonomous movement.
Study: NCT04435275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Assistant first, then Human Coach
Description: Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Assistant first, then Human Coach
Description: Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Coach first, then Virtual Assistant
Description: instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Coach first, then Virtual Assistant
Description: instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).
Study: NCT04889625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A C3
Description: Test Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A C3
Description: Test Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lenses
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lenses
Description: Control Lens
Study: NCT05835856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual coach with Google Nest Hub (2e generation) group
Description: The coaching device used is Google Nest Hub (2e generation). This is a connected speaker enriched with a 7-chip touch screen. It has a loudspeaker and 3 microphones, making interaction possible.
Study: NCT05163652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
Study: NCT05835856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual coach with Gatebox device
Description: The coaching device used is the Gatebox, a hologram like device which the user can interact. There are internal sensors such as a camera and a microphone allow the user to converse with the projected character. It connects to the Internet via a wireless LAN. With infrared rays and Bluetooth, it can also be connected to household appliances and other devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual coach with CelesTE robot
Description: The coaching device used is the CelesTE robot, a prayer companion designed for Christian Catholic users.The intended main function of CelesTE is to be a guardian angel, especially thought for elderly people. It can be a prayer companion, and contains a vast number of teachings, including the whole Bible. Its AI is capable of keeping a short conversation, in which the user may ask and receive an answer about a sensitive topic (such as happiness, death, faith, etc.). It can also printout a selection of contents.~The coaching device CelesTE will be substituted by DarumaTO for the Japanese centers.

Intervention type: OTHER
Group type: OTHER
Intervention: booklet
Description: Participant in the control group will receive a booklet containing information and activities on well-being
Study: NCT04760028

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adjusting the depth of anesthesia
Description: After the main procedure, the depth of anesthesia can be adjusted as needed
Study: NCT05600855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens.
Study: NCT05760781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion